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Identiﬁcation of novel urinary biomarkers for assessing
disease activity and prognosis of rheumatoid arthritis
Yune-Jung Park1,2, Seung-Ah Yoo2, Daehee Hwang3, Chul-Soo Cho2,4 and Wan-Uk Kim2,5
To optimize treatment for rheumatoid arthritis (RA), it is ideal to monitor the disease activity on a daily basis because RA activity
ﬂuctuates over time. Urine can be collected routinely at home by patients. Recently, we identiﬁed four urinary biomarker
candidates—gelsolin (GSN), orosomucoid (ORM)1, ORM2 and soluble CD14 (sCD14)—in RA patients through transcriptomic
and proteomic studies. Here, we investigated the clinical signiﬁcance of the aforementioned urinary biomarker candidates in a
prospective manner. For the ﬁrst time, we found that urinary ORM1, ORM2 and sCD14 levels, but not GSN, were elevated in RA
patients and had a positive correlation with the status of the disease activity. In particular, urine tests for ORM 1, ORM 2 and
sCD14 efﬁciently represented the presence of high RA activity without the need for measuring blood markers. In a parallel study,
a more rapid radiographic progression over 3 years was observed in patients with higher ORM2 levels. Combined measurements
of urinary ORM2 and serum C-reactive protein synergistically increased the predictability of the radiographic progression of RA
(odds ratio: 46.5). Collectively, our data provide evidence that blood-free, urinary biomarkers are promising surrogates for
assessing disease activity and prognosis of RA. We anticipate that our urinary biomarkers will provide novel candidates for
patient-driven measurements of RA activity at home and can shift the paradigm from blood to urine testing in the assessment
of RA activity and prognosis in hospitals.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
that progressively destroys cartilage and bone. The assessment
of the status of RA is a central aspect of patient care. The
reduction of RA activity is the major target of therapeutic
interventions.1 Erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) are the most commonly used blood
markers to evaluate disease activity of RA. However, ESR stays
elevated for some time after inﬂammation is reduced by
treatments, and it can be inﬂuenced by anemia and age.2,3
CRP is non-speciﬁcally inﬂuenced by infection. Importantly,
ESR and CRP may remain normal in more than a third of RA
patients at presentation irrespective of disease activity.4,5 The
disease activity score 28 (DAS28), which is based on counts of
tender and swollen joints and ESR (or CRP) measurements,
has been widely used for RA assessment. However, it requires
speciﬁc expertise. Anti-cyclic citrullinated peptide antibody
(ACPA), a representative diagnostic marker of RA, can help
predict radiographic progression. However, ACPA does not
usually correlate with disease activity of RA.6 In these instances,
there remains an unmet need for alternative biomarkers that
can complement conventional serum measures to precisely
monitor disease activity of RA.
Another important issue in assessing RA activity is that there
is no daily-based measure of activity, such as exists for glucose
or blood pressure monitoring. It is well known that mean
disease activity assessed by ESR and CRP at regular intervals is
the major determinant in predicting joint damage and extra-
articular complications associated with RA,1 including cardio-
vascular diseases and osteoporosis. In addition, cumulative
levels of DAS28 correlate well with RA progression and
complications.1 Thus, maintaining a minimal residual level of
disease activity (DAS28 below 2.6), as suggested by the target-
to-treat strategy, is critical for the optimal treatment of RA.1
To optimize the treatment for RA, it would be ideal to monitor
RA activity on a daily basis, as can be done for blood pressure
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and glucose, because the activity of RA ﬂuctuates over time.
We could then titrate anti-rheumatic medications according to
the mean disease activity. However, in clinical practice, most
rheumatologists cannot consistently monitor RA activity on a
daily or weekly basis when patients only visit hospitals every
1–2 months. Another reason for this may be the lack of time
during outpatient visits and the lack of simple reliable
biomarkers to perform this assessment. If patients could
periodically perform self-diagnostic tests for surrogate markers
of RA activity at home without visiting the hospital, cumulative
or multiple test results may more accurately reﬂect RA activity
than a single set of measurements taken at the hospital. In
addition, this would enable doctors to more tightly control RA
progression and complications.
Urinary biomarkers for RA may be a way to address this
issue. Urine can be collected routinely at home by patients.
Urinary biomarkers provide a complementary dimension to
serum measures for some diseases that frequently involve
the kidney, including diabetes mellitus and systemic lupus
erythematosus.7,8 Recently, we identiﬁed four urinary bio-
marker candidates—gelsolin (GSN), orosomucoid (ORM)1,
ORM2 and soluble CD14 (sCD14)—in RA patients through
the integration of differentially expressed proteins with gene
expression data from joint tissues and peripheral blood mono-
nuclear cells.9 In a subsequent proof-of-concept trial, we also
demonstrated that urinary sCD14 levels were predictive of RA
activity.9 In the present study, we investigated the clinical
signiﬁcance of the four urinary biomarker candidates in a
prospective manner, focusing on their role in assessing RA
activity and prognosis.
MATERIALS AND METHODS
Patients and controls
Two hundred sixty-four patients with RA and one hundred eight-
seven control subjects were consecutively recruited from outpatients at
our hospital. All RA patients fulﬁlled the 1987 American College of
Rheumatology criteria for RA.10 Urine samples were obtained from
patients with RA and non-RA controls. Non-RA controls were
recruited from healthy subjects without inﬂammatory arthritis. The
following subjects were excluded: those with severe cardiac diseases,
renal diseases that could affect glomerular ﬁltration rate, current or
chronic infections, pregnancy or a history of malignancy. The study
protocol was approved by the Institutional Review Board of the
Catholic Medical Center (VC12RISI0191). All patients gave written
informed consent to the study protocol.
Determination of RA activity and severity
Disease activity of RA was evaluated with the DAS28ESR.
11 The severity
of RA was assessed by evaluating radiographic damage on X-rays of
the hands and feet of subjects. Radiographs of the hands and feet were
taken at baseline and annually thereafter. Radiographic severity was
scored in chronologic order for erosions and joint space narrowing
according to the Sharp/van der Heijde method.12 Severity scores were
determined by two board-certiﬁed physicians who were blinded to
each patient’s identity or clinical status. The inter-observer variability
described by the interclass correlation coefﬁcient was 0.91. Joint space
narrowing and erosion scores were summed to give a total radio-
graphic progression score. Erosion and narrowing progression scores
were calculated by subtracting the initial score from the score after a
3-year follow-up. Radiographic progression was deﬁned as a progres-
sion score⩾ 4.13
ELISA
Urine samples were collected from the ﬁrst or second urination of the
day into sterile 500 ml plastic tubes containing 0.05% sodium azide.
Urine samples were centrifuged at 14 000 g for 10 min at 4 °C
immediately after collection. The clariﬁed supernatants were stored
at − 70 °C until used for analysis. Urinary concentrations of sCD14,
GSN, ORM1 and ORM2 were also determined by ELISA, as described
previously.9
Statistical analysis
Comparisons between the two groups were performed by a
Mann–Whitney U-test. A χ2 test was used to compare proportions.
Spearman correlation coefﬁcients were used to describe the association
between two variables. Radiographic progression events (any increase
in an Sharp/van der Heijde score⩾ 4) were investigated to determine
the presence of radiographic progression after 3 years. To evaluate
the ability of urinary proteins to predict high disease activity
(DAS2845.1) and radiographic progression, receiver operating
characteristic (ROC) curves were plotted. We also tested whether
combined urinary measurements, such as ORM1+ORM2, ORM1
+sCD14 and ORM2+sCD14, had different predictive powers for
disease activity. For this, positive values for ORM1, ORM2 and
sCD14 were deﬁned as those above the cutoff levels of 0.34, 0.15
and 22.4 ng ml− 1, respectively. Optimal cutoff levels for urinary
proteins were determined by ROC curves. The number of patients
with both positive marker values and high disease activity scores
(DAS2845.1) was 54, 61 and 63 for ORM1, ORM2 and sCD14,
respectively. The number of patients who were double-positive for two
urinary proteins was 46, 49 and 51 for ORM1 and ORM2, ORM1 and
sCD14, and ORM2 and sCD14, respectively. The number of patients
who were double-negative for two urinary proteins was 39, 57 and 50
for ORM1 and ORM2, ORM1 and sCD14, and ORM2 and sCD14,
respectively. Probability plots, which were based on serum CRP levels
in patients who had higher urinary ORM2 levels (⩾ 2.21 ng ml−1, the
highest tertile) versus lower urinary ORM2 levels (o 2.21 ng ml− 1),
were used to display radiographic progression. A multivariate logistic
regression analysis was performed to determine signiﬁcant and
independent contributions of speciﬁc variables to the radiographic
progression. Multivariate models included all covariates with associa-
tions from the univariate models with a P value⩽ 0.20. All reported
P values were two-tailed, with a P valueo0.05 indicating statistical
signiﬁcance.
RESULTS
Characteristics of study population
Baseline characteristics of the 264 RA patients and 187 non-RA
controls are shown in Supplementary Table 1. The mean ages
of RA patients and non-RA controls were 53.2 and 52.9 years,
respectively. The median glomerular ﬁltration rate in RA
patients was higher than that in control subjects. No signiﬁcant
difference was found in sex, serum creatinine, percentage of
patients with hypertension or percentage with diabetes mellitus
between the two groups. A total of 173 (65.5%) patients
received methotrexate, 194 (73.4%) received hydroxy-
chloroquine, 26 (9.8%) received anti-tumor necrosis factor-α
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(anti-TNF-α) therapy and 198 (75.0%) were treated with
low-dose prednisolone (⩽10mg per day).
Correlation of urinary protein levels with RA activity
Urinary levels of four proteins (GSN, ORM1, ORM2 and
sCD14), after adjustment for urine creatinine, in RA patients
(n= 264) were signiﬁcantly higher than those in control
subjects (n= 187; Figure 1a–d). There was no difference in
the four urinary protein levels in relation to the use of
medications, including prednisolone, methotrexate, hydroxy-
chloroquine and anti-TNF-α therapy (data not shown). To
assess the clinical signiﬁcance of urinary proteins, we examined
the association of the four proteins with several parameters
representing disease activity of RA. When we divided RA
patients into three groups based on DAS28 results (low:
DAS28⩽ 3.2 (n= 76), moderate: 3.2oDAS28⩽ 5.1 (n= 114)
and high: DAS2845.1 (n= 74)), urinary ORM1, ORM2 and
sCD14 levels increased in proportion to DAS28 (Figure 2a)
values. In univariate analyses, ORM1, ORM2 and sCD14 levels
were positively correlated with blood inﬂammatory marker
levels, such as ESR and CRP (Figure 2b). Particularly, ORM2
showed the highest correlation co-efﬁciency with CRP
(r= 0.55), which was similar to the correlation between ESR
and CRP (r= 0.54). Moreover, urinary ORM2 was positivity
correlated with urinary sCD14 (r= 0.37), a well-known serum
biomarker of RA activity.14,15 However, ORM1 showed a weak
correlation with ESR and CRP (Figure 2b). Interestingly,
an analysis of clustering correlations showed different patterns
between RA and non-RA controls, particularly in the correla-
tions of ORM1 with ORM2 and sCD14 (Supplementary
Figure 1).
Next, we compared the diagnostic power of four urinary
proteins for predicting high disease activity (DAS2845.1) with
the diagnostic power of conventional markers for chronic
inﬂammation, including CRP, hemoglobin and albumin.
When we analyzed ROC curves of models, the area under
the curve (AUC) of sCD14 was 0.59 (95% conﬁdence interval
(CI): 0.47–0.65) and that of ORM1 was 0.61 (0.47–0.63). The
AUC of ORM2 was 0.66 (0.56–0.74), which was comparable to
that of CRP (0.66 (0.57–0.73); Figure 2c). However, GSN had
no signiﬁcant association with high disease activity (Figure 2c).
No signiﬁcant difference in AUC was found between OMR2
and CRP levels, suggesting that urine ORM2 could replace
serum CRP in predicting high RA activity. Moreover, when two
urinary biomarkers were simultaneously analyzed as a com-
bined measure of activity, their sensitivity and speciﬁcity for
predicting high disease activity were better than those when
using a single urinary marker (Figure 2d). Particularly, for RA
patients with elevated ORM1 and ORM2 in their urine,
sensitivity and speciﬁcity for predicting high activity were
98% and 76%, respectively. These results suggest that urinary
tests using one or two biomarkers out of ORM1, ORM2
and sCD14 could help clinicians monitor disease activity
as efﬁciently as serum CRP, a conventional inﬂammatory
marker of RA.
ORM2 as a urinary biomarker for RA progression
It is well known that accumulated disease activity can
determine the severity and prognosis of RA.1,16,17 Based on
our ﬁnding that urinary protein levels could reﬂect disease
activity, we further investigated whether these urinary proteins
could serve as a predictor of radiographic progression.
Figure 1 Comparison of urinary levels of biomarker candidates between patients with rheumatoid arthritis (RA) and non-RA controls. Levels
of four urine proteins, including (a) orosomucoid (ORM) 1, (b) ORM2, (c) soluble CD14 (sCD14) and (d) gelsolin (GSN) were determined
in the urine of RA patients (n=264) and non-RA controls (n=187) by ELISA. The data are presented as the mean± standard error of
mean (s.e.m.). *Po0.05 and **Po0.01.
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The median value of baseline radiographic scores was 40.9
(interquartile range: 15.7–64.3) and the mean value at a 3-year
follow-up was 44.6 (interquartile range: 13.6–69.6). When
baseline clinical parameters and urinary protein levels in RA
patients with (n= 24) or without radiographic progression
(n= 240) were compared, progressive RA patients had longer
disease durations, higher glomerular ﬁltration rate, elevated
ESR and CRP levels and more ACPA (Supplementary Table 2),
which is in agreement with previous reports.18 The group
with radiographic progression had higher ORM2 levels than
the non-progression group (3.22 ngml− 1 (0.36–5.42) and
0.26 ngml− 1 (0.17–0.60), respectively, Po0.001; Figure 3a).
Interestingly, patients with higher urinary ORM2 levels
(⩾ 2.21 ngml−1) at baseline had more severe radiographic
progression after 3 years than those with lower urinary ORM2
levels (o2.21 ngml− 1; 44.6 (18.7–62.1) and 38.8 (13.5–69.4),
respectively, P= 0.005). These data suggest that urinary ORM2
can serve as a surrogate biomarker to predict RA progression.
Multivariate logistic regression analysis was performed to
assess whether urinary protein levels could independently
predict radiographic progression. Our results showed that
urinary ORM2 levels signiﬁcantly increased the risk of the
Figure 2 Relationship of urinary ORM1, ORM2 and sCD14 levels with RA activity. (a) Urinary protein (ORM1, ORM2 and sCD14) levels in
relation to disease activity of RA. RA activity was assessed with the disease activity score 28ESR (DAS28ESR) as low activity at
DAS28 ⩽3.2 (n=76), moderate activity at 3.2o DAS28 ⩽5.1 (n=114), and high activity at DAS28 45.1 (n=74). The data are
presented as the mean± s.e.m. ***Po0.001. (b) Clustering correlations of urinary protein levels with the blood inﬂammatory markers of
RA. *Po0.05, **Po0.01 and ***Po0.001. The power of the correlation is represented by the color and size of the circles. (c) Receiver
operating characteristic (ROC) curves analyses to assess the association of high RA activity with urinary biomarker proteins, including
ORM1, ORM2 and sCD14. High activity was deﬁned as DAS28 45.1. The area under the curve was 0.61 for ORM1 (P=0.020), 0.66 for
ORM2 (P=0.001), 0.57 for gelsolin (GSN, P=0.12), 0.59 for (P=0.071), 0.37 for albumin (P=0.009), 0.40 for hemoglobin
(Hb, P=0.040), 0.71 for ESR (Po0.001) and 0.66 for CRP (Po0.001). (d) Sensitivity and speciﬁcity of urinary protein markers for
assessing high RA activity (DAS28 45.1) when their optimal cutoff values are introduced. The cutoff values were 0.34 ng ml−1 for ORM1,
0.15 ng ml−1 for ORM2 and 22.4 ng ml−1 for sCD14.
Urinary biomarkers for RA
Y-J Park et al
4
Experimental & Molecular Medicine
radiographic progression of RA (OR= 1.25, 95% CI:
(1.01–1.54), P= 0.044; Table 1), indicating that urinary
ORM2 is an independent risk factor for RA progression.
However, ORM1, sCD14 or GSN levels did not show a
statistically signiﬁcant association with radiographic progres-
sion (Table 1). To compare the diagnostic performance of
urinary ORM2 for radiographic progression with that of serum
CRP, we performed an ROC curve analysis using blood
ESR/CRP and urine ORM2. Our results revealed that the
AUC for ORM2 was 0.792 (0.690–0·901; Figure 3b), which was
comparable to the AUC for ESR (0.813 (0.734–0.889)), a
conventional blood marker used to predict RA progression.19
The AUC for serum CRP was 0.890 (0.83–0.94).
Complementary value of urinary ORM2 to current measures
for RA progression
We further investigated whether urinary ORM2 plus serum
CRP can better predict radiographic progression than each
Figure 3 Correlation of urinary ORM2 levels with radiographic progression of RA. (a) Urinary levels of ORM1, ORM2 and sCD14 in relation
to the radiographic severity of RA. Radiographic severity was assessed by evaluating radiographic damage on X-rays of the hands and feet,
which were taken at baseline and annually thereafter. Radiographic progression was deﬁned as a progression score ⩾4. (b) ROC curve
analysis for radiographic progression revealed that ORM2 had an area under the curve (AUC) comparable to those of ESR and CRP. The
AUC was 0.79 for ORM2 (Po0.001), 0·81 for ESR (Po0.001) and 0.89 for CRP (Po0.001). (c) Probability plots for radiographic
progression in relation to serum CRP levels in RA patients stratiﬁed by urinary ORM2 levels (high versus low ORM2).
Table 1 Multivariate logistic regression analysis for predicting radiographic progression using conventional risk factors plus
urinary protein markers
Model Odds ratio (95% CI) P-value
Model 1 (Basic model+ORM1, per 1-s.d. increase) 1.27 (0.90–1.79) 0.166
Model 2 (Basic model+ORM2, per 1-s.d. increase) 1.25 (1.01–1.54) 0.044
Model 3 (Basic model+GSN, per 1-s.d. increase) 0.79 (0.59–1.05) 0.101
Model 4 (Basic model+CD14, per 1-s.d. increase) 1.00 (0.99–1.00) 0.501
Abbreviations: CI, conﬁdence interval; GSN, gelsolin; ORM, orosomucoid (α1-acid glycoprotein).
Basic model included age, disease duration, C-reactive protein, anti-cyclic citrullinated peptide antibody positivity and glomerular ﬁltration rate at baseline.
Logistic regression was used to obtain basic model-adjusted odds ratios for the presence of radiographic progression.
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individual parameter. To do this, we stratiﬁed patients based
on urinary ORM2 concentrations. As shown in Figure 3c,
patients with high urinary ORM2 (⩾ 2.21 ngml−1) showed a
higher probability of radiographic progression than those with
low urinary ORM2. The predicted probability of joint destruc-
tion at the median CRP level was 0.70 in the high ORM2 group
and 0.22 in the low ORM2 group (Figure 3c). Based on these
observations, we further analyzed whether urinary ORM2
could provide additional predictive value for radiographic
progression when combined with serum CRP or ESR. To do
this, we categorized RA patients into two groups based on
positive levels for ORM, CRP and ESR (Table 2). The positive
cutoff values were as follows: urinary ORM242.21 ng ml-1,
CRP was40.3 mg dl− 1, ESR for men4age/2mmh− 1 and ESR
for women was4(age+10)/2 mmh− 1. The results showed that
RA patients who were positive for both ORM2 and serum CRP
had signiﬁcantly higher adjusted odds ratios (ORs) of radio-
graphic progression than patients positive for a single marker
or negative for both (Table 2). Patients who were positive for
both ORM2 and ESR showed a similar trend. Speciﬁcally, in
RA patients who were positive for both ORM2 and
CRP (n= 43), the adjusted OR was signiﬁcantly higher (46.45
(5.23–412.73), Po0.001) compared with that of patients who
were negative for both (n= 128). This OR was also much
greater than the OR obtained by a conventional combinatory
model with serum CRP and ESR (OR= 4.09, P= 0.039;
Table 2). A similar trend was found by a tree analysis to ﬁnd
the best combination of cutoff values to predict radiographic
progression (Supplementary Figure 2). Taken together, these
data suggest that urinary ORM2 can offer complementary
dimensions to current serum parameters for RA activity and
prognosis. It has an even better predictive power for RA
progression than a combined measure of ESR and CRP.
DISCUSSION
The goal of RA treatment is to maintain minimal residual
disease levels or to achieve complete remission.1,20 Because the
DAS28 score is one of the best measures to determine RA
activity, rheumatologists measure DAS28 scores routinely and
use it as one of the justiﬁcations for recommending a change in
treatment.20 However, RA activity ﬂuctuates over time, and
DAS28 scores in patients who transiently improved just before
the patient’s visit may be misleadingly low and the actual
mean activity between the visits high. Therefore, regular self-
monitoring of RA activity and the identiﬁcation of surrogate
markers is required so that actual RA activity correlates with
DAS28. Urine can be collected daily at home, non-invasively in
large quantities, and urine is more stable than other bio-
ﬂuids.21 It may serve as a potentially rich source of biomarkers
that can indicate systemic inﬂammation through the excretion
of overproduced proteins.22 Here, we introduced an innovative
approach using the patients’ urine to assess the activity and
progression of RA. We found that three urinary biomarker
candidates—ORM1, ORM2 and sCD14—correlated well with
RA activity. Importantly, urinary ORM2 levels showed the
highest correlation with DAS28 scores, which was comparable
to that of serum CRP. Given that urinary ORM2 had an AUC
comparable to that of serum CRP for patients with high RA
activity (DAS2845.1), it might be able to replace blood
measures for RA activity, thus eliminating the requirement
for blood sampling.
RA is a multifaceted disease in which the evaluation of any
one of the available measures does not always provide reliable
information on a patient’s status.23–25 The fact that there are
more than 63 currently available measurement tools for RA
disease activity reﬂects the efforts to search for models that
could best describe this disease’s status.26 In addition, because
of the pathological complexity of RA,23 a single aspect of
disease activity may not be sufﬁcient in most measurement
indices. Rather, combinations of several biomarkers might offer
the possibility to enhance diagnostic accuracy. Here, we found
that the combinatory analysis of two biomarkers out of the set
of ORM1, ORM2 and sCD14 in the urine of RA patients
showed a better diagnostic sensitivity and speciﬁcity in
predicting high RA activity (DAS2845.1) than using a
single biomarker. Speciﬁcally, for RA patients with high levels
of ORM1 and ORM2 in their urine, the sensitivity and
speciﬁcity for predicting high RA activity were 98% and
76%, respectively. Elevated CRP alone (40.3 mg dl− 1) showed
rates of 75% and 60% for the sensitivity and speciﬁcity,
respectively, of predicting high RA activity (data not shown).
These results suggest that urine tests using the above biomarker
sets could better discriminate active RA from inactive RA
without the need for blood tests, such as those for ESR and
CRP. The present study provides a rationale to develop urinary
kits that can be utilized at home for self-assessment of RA
activity. Similarly, urinary ORM1, ORM2 and sCD14
Table 2 Multivariate logistic regression analysis of a
combination of urinary proteins with blood markers for
predicting radiographic progression
Odds ratio (95% CI) P-value
Model+ORM2-CRP combination
Negative (n=128) 1
One positive (n=93) 8.72 (1.01–77.68) 0.048
Two positive (n=43) 46.45 (5.23–412.73) 0.001
Model+ORM2-ESR combination
Negative (n=85) 1
One positive (n=110) 1.09 (0.25–4.84) 0.309
Two positive (n=69) 3.94 (1.10–15.69) 0.042
Model+CRP-ESR combination
Negative (n=90) 1
One positive (n=84) 1.70 (0.35–3.84) 0.268
Two positive (n=90) 4.09 (1.07–15.55) 0.039
Abbreviations: CI, conﬁdence interval; CRP, C-reactive proteins; ESR, erythrocyte
sedimentation rate; ORM, orosomucoid (α1-acid glycoprotein).
Model included the following baseline variables: disease duration, anti-cyclic
citrullinated peptide antibody positivity, and glomerular ﬁltration rate. Logistic
regression was used to obtain model 1-adjusted odds ratios for the presence of
radiographic progression.
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might offer new diagnostic targets for other forms of chronic
arthritis.
The accumulated disease activity of RA mainly affects
RA prognosis and extra-articular complications, such as
atherosclerosis.1,27,28 Our results demonstrating the association
of ORM1, ORM2 and sCD14 with RA activity prompted us to
investigate the role of these biomarkers in predicting RA
progression. Multivariate logistic regression analysis was per-
formed to determine whether ORM1, ORM2 and sCD14 could
predict radiographic progression after 3 years. Our results
showed that urinary ORM2, but not ORM1 or sCD14, was an
independent risk factor for the prediction of the radiographic
progression of RA (Table 1). ORM2 could provide additional
beneﬁts to the use of current blood markers ESR and CRP
(Table 2). Importantly, in patients who had elevated levels of
both ORM2 (⩾ 2.21 ngml−1) and CRP (4 0.3mg dl− 1),
the adjusted OR was 46.5. These data clearly show that
urinary ORM2, as a non-invasive diagnostic biomarker,
could be a promising parameter for the prediction of the
radiographic progression of RA. It also may offer complemen-
tary dimensions to the current serum parameters used for RA
prognosis.
In summary, in a single-center prospective study, we found
that urinary ORM1, ORM2 and sCD14 levels were elevated in
RA patients and correlated well with the status of the disease
activity. In particular, the use of urine tests for ORM1, ORM2
and sCD14 (without the need for blood ESR/CRP tests)
efﬁciently represented the presence of high RA activity.
In parallel, a more rapid radiographic progression over
3 years was observed in patients with higher ORM2 levels.
Furthermore, the combination of urinary ORM2 and serum
CRP synergistically increased the predictability of radiographic
progression. Our data provide evidence that blood-free urinary
biomarkers are promising surrogates for assessing disease
activity and prognosis of RA. We anticipate that our urinary
biomarkers will provide novel candidates for patient-driven
measurements of RA activity at home and may shift the
paradigm from blood to urine testing in the assessment of
RA activity and prognosis in hospitals. We are currently
developing a new diagnostic kit and portable machine (FREND
System at http://www.nanoentek.com) to accurately measure
concentrations of ORM1, ORM2 and sCD14 in a drop of urine
within 10min (Supplementary Figure 3).
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